Payment overview · 2025
General Payments
$237.76
14 reported records · 9 companies
Healthcare provider profile · identity verified
Aaron Frey, MD
Allopathic & Osteopathic Physicians|Family Medicine · SEYMOUR, IN · NPI 1275913378
Verified facts
What the public records show
CMS Open Payments records show Aaron Frey, MD received $237.76 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.63 | 33.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.70 | 13.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.61 | 12.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.78 | 10.8% | 1 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $22.99 | 9.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.91 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.79 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.91 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2.44 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.76 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $2.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 128 |
| Omeprazole | Omeprazole | 429 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 395 | 99 |
| Lisinopril | Lisinopril | 392 | 97 |
| Meloxicam | Meloxicam | 366 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 98 |
| Simvastatin | Simvastatin | 323 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 312 | 86 |
| Trazodone Hcl | Trazodone Hcl | 311 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 75 |
| Gabapentin | Gabapentin | 261 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 240 | 59 |
| Losartan Potassium | Losartan Potassium | 237 | 63 |
| Allopurinol | Allopurinol | 204 | 46 |
| Furosemide | Furosemide | 191 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 48 |
| Eliquis | Apixaban | 167 | 37 |
| Sertraline Hcl | Sertraline Hcl | 160 | 36 |
| Glimepiride | Glimepiride | 159 | 46 |
| Metformin Hcl | Metformin Hcl | 156 | 40 |
| Potassium Chloride | Potassium Chloride | 149 | 37 |
| Famotidine | Famotidine | 131 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 27 |
| Atenolol | Atenolol | 124 | 31 |
| Metformin Hcl Er | Metformin Hcl | 111 | 31 |
| Prednisone | Prednisone | 110 | 95 |
| Alendronate Sodium | Alendronate Sodium | 109 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 25 |
| Mounjaro | Tirzepatide | 96 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 30 |
| Montelukast Sodium | Montelukast Sodium | 94 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 23 |
| Tramadol Hcl | Tramadol Hcl | 89 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 80 |
| Donepezil Hcl | Donepezil Hcl | 87 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 34 |
| Trulicity | Dulaglutide | 80 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 50 |
| Synthroid | Levothyroxine Sodium | 74 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 18 |
| Bupropion Xl | Bupropion Hcl | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Lorazepam | Lorazepam | 63 | 15 |
| Ozempic | Semaglutide | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 12 |
| Finasteride | Finasteride | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 43 |
| Farxiga | Dapagliflozin Propanediol | 48 | 13 |
| Celecoxib | Celecoxib | 47 | 14 |
| Clonazepam | Clonazepam | 46 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Ramipril | Ramipril | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Torsemide | Torsemide | 43 | 15 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 30 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Estradiol | Estradiol | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluorouracil | Fluorouracil | 19 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.76 · 14 records | ABBVIE INC. | AREXVY, CREON, FARXIGA, GeneXpert, INGREZZA, LINZESS, MOUNJARO, NEXLETOL, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error